Meghan J. Mooradian, MD

Articles

Emerging Concepts on the Role of Immunotherapy in NSCLC

February 20th 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC

February 13th 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients

February 13th 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC

January 30th 2023

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Applying Molecular Biomarkers in Treatment Decision Making in NSCLC

January 30th 2023

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

The Role of Molecular Testing In Metastatic NSCLC

January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

April 29th 2022

Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.

Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

April 22nd 2022

Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.

Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

April 22nd 2022

Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.

Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

April 15th 2022

Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.

Overview of Actionable Mutations and Molecular Profiling in NSCLC

April 15th 2022

Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.